Results 21 to 30 of about 3,123 (163)

Determination of plasma protein binding of dalbavancin

, 2022
OBJECTIVES: Dalbavancin is a lipoglycopeptide with a long half-life, making it a promising treatment for infections requiring prolonged therapy, such as complicated Staphylococcus aureus bacteraemia.
Turner, Nicholas A, Holland, Thomas L, Zaharoff, Smitha, Lodise, Thomas P, Xu, Allan   +4 more
core   +2 more sources

Emergence of Dalbavancin, Vancomycin, and Daptomycin Cross-resistance in MRSA During Long-term LVAD Suppression With Vancomycin Followed by Dalbavancin: Genomic Insights and Synergy With Cefadroxil. [PDF]

Open Forum Infect Dis
We present a case in which vancomycin and dalbavancin exposure preceded emergence of nonsusceptibility to dalbavancin, vancomycin, and daptomycin in a strain of methicillin-resistant Staphylococcus aureus in the setting of a left ventricular assist ...
Stohs EJ, Alexander BT, Fey PD, Foreman MCL, Xu L, Penewit K, Waalkes A, Salipante SJ, Werth BJ.   +8 more
europepmc   +2 more sources

Breaking Down Barriers: CorA Effectively Targets Staphylococcal Biofilms in Vitro and in Vivo. [PDF]

ChemMedChem
Corallopyronin A (CorA), a natural alpha‐pyrone antibiotic, penetrates Staphylococcus aureus biofilms and inhibits RNA polymerase. This work demonstrates CorA's superior efficacy compared to rifampicin and dalbavancin in reducing viable loads in biofilms both in vitro and in vivo. Graphic created in https://BioRender.com.
De Benedetti S, Kirilov NK, Zeng H, Ade C, Bodenstein I, Förster M, Abdel-Wadood N, Aljohmani A, Krasteva-Christ G, Yildiz D, Junker S, Khalid SJ, Rox K, Schrey H, Große M, Schiefer A, Becker SL, Pfarr K, Hoerauf A, Bischoff M, Müsken M, Schneider T.   +21 more
europepmc   +2 more sources

Leukocytoclastic Vasculitis Induced by Dalbavancin: A Case Report. [PDF]

Am J Case Rep
Objective: Rare disease Background: Dalbavancin is a lipoglycopeptide antibiotic largely used to treat serious and complex bacterial infections, particularly those caused by gram-positive bacteria. Its main advantages include a prolonged half-life, which
Scaglione V, Cola M, Sasset L, Fortarezza F, Casarin C, Trevenzoli M, Dei Tos AP, Cattelan A.   +7 more
europepmc   +2 more sources

Dalbavancin in Gram-positive periprosthetic joint infections

, 2022
OBJECTIVES: The unique properties of dalbavancin (DAL) emphasize the need to explore its clinical benefits to treat periprosthetic joint infections (PJIs). The present study aimed to compare the treatment outcome of dalbavancin with Standard of Care (SoC)
Hartmann, Susana,, Reitsamer, Michael,, Söderquist, Bo,, Frank, Bernhard J. H.,, Dominkus, Martin,, Hofstaetter, Jochen G.,, Aichmair, Alexander,, Simon, Sebastian,, Hinterhuber, Laetitia,   +8 more
core   +1 more source

A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections

Antibiotics, 2023
Bone and joint infections (BJI) require prolonged antimicrobial treatment, leading to lengthy hospitalizations, high costs, the risk of nosocomial infections, and the development of antimicrobial resistance.
Dimitra Dimopoulou, Elpis Mantadakis, Christos Koutserimpas, George Samonis   +3 more
doaj   +1 more source

Successful treatment of methicillin-sensitive Staphylococcus aureus tricuspid-valve endocarditis with dalbavancin as an outpatient in a person who injects drugs: A case report

International Journal of Infectious Diseases, 2020
There is a paucity of literature on the use of dalbavancin, a long-acting lipoglycopeptide, in infective endocarditis. Existing case reports have investigated dalbavancin in endocarditis as a sequential treatment after clearance of bacteria from the ...
Aaron Hakim, Hannan Braun, David Thornton, Judith Strymish   +3 more
doaj   +1 more source

Multicenter clinical experience of real life Dalbavancin use in gram-positive infections

International Journal of Infectious Diseases, 2019
Dalbavancin, a lipoglycopeptide with prolonged half-life approved for the treatment of acute bacterial skin and soft tissue infections, can be used for the treatment of infections caused by gram-positive bacteria requiring long term treatment such as ...
S. Wunsch, R. Krause, T. Valentin, J. Prattes, O. Janata, A. Lenger, R. Bellmann-Weiler, G. Weiss, I. Zollner-Schwetz   +8 more
doaj   +1 more source

Effect of Dalbavancin on Staphylococcal Biofilms When Administered Alone or in Combination With Biofilm-Detaching Compounds

Frontiers in Microbiology, 2020
Microorganisms grown in biofilms are more resistant to antimicrobial treatment and immune system attacks compared to their planktonic forms. In fact, infections caused by biofilm-forming Staphylococcus aureus and Staphylococcus epidermidis are a large ...
Miglë Žiemytė, Juan C. Rodríguez-Díaz, María P. Ventero, Alex Mira, Alex Mira, María D. Ferrer, María D. Ferrer   +6 more
doaj   +1 more source

Dalbavancin in the Community Emergency Department [PDF]

, 2020
Introduction Dalbavancin is an antibiotic within the class of medications known as lipoglycopeptides. This medication is given to patients presenting to the hospital with acute skin and skin-structure infections (ABSSSI).
Johnson, Wesley
core   +1 more source